Trial Profile
A Multicentre, Open Label, Non-randomised, Non-interventional, Observational Safety Study in Subjects With Type 2 Diabetes Mellitus, Starting or Switching to NovoMix 30 Treatment
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Jan 2017
Price :
$35
*
At a glance
- Drugs Insulin aspart/insulin protamine aspart (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 13 Mar 2012 New trial record